Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
about
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
P2860
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@ast
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@en
type
label
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@ast
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@en
prefLabel
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@ast
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@en
P2093
P2860
P356
P1476
Effectiveness and Cost-Effecti ...... ed States: A Decision Analysis
@en
P2093
David Stenehjem
Diana Brixner
Gary Oderda
Jerald Radich
Kuo Kuan-Ling
Martina Kluibenschaedl
Ursula Rochau
P2860
P304
P356
10.1155/2015/982395
P50
P577
2015-12-10T00:00:00Z